Figures & data
Figure 1. Gut microbiota dysbiosis in NTM-LD patients.
![Figure 1. Gut microbiota dysbiosis in NTM-LD patients.](/cms/asset/3f0f00df-08d5-493b-8805-1f6d1d167cf1/kgmi_a_2361490_f0001_oc.jpg)
Figure 2. P. copri predominantly induce TLR2 pathway and NTM-LD patients had compromised TLR2 activation activity.
![Figure 2. P. copri predominantly induce TLR2 pathway and NTM-LD patients had compromised TLR2 activation activity.](/cms/asset/47ec3d5d-0b59-442b-b6a2-7cad477ab087/kgmi_a_2361490_f0002_oc.jpg)
Figure 3. Gut microbiota dysbiosis and compromised TLR2 activation activity in mice receiving four antibiotics.
![Figure 3. Gut microbiota dysbiosis and compromised TLR2 activation activity in mice receiving four antibiotics.](/cms/asset/5a127a5d-b96b-4f90-ad67-c274555c2042/kgmi_a_2361490_f0003_oc.jpg)
Figure 4. Transcriptomic analysis of lung tissues of ABX mice.
![Figure 4. Transcriptomic analysis of lung tissues of ABX mice.](/cms/asset/d9c4d6fe-18ac-44b3-a994-258aa15f91fd/kgmi_a_2361490_f0004_oc.jpg)
Figure 5. Administration of TLR2 agonist or treatment of P. copri restored immune response and ameliorated NTM-LD.
![Figure 5. Administration of TLR2 agonist or treatment of P. copri restored immune response and ameliorated NTM-LD.](/cms/asset/c905d73b-0c97-4591-8866-ab6cf2d8c806/kgmi_a_2361490_f0005_oc.jpg)
Figure 6. Administration of capsular polysaccharide of P. copri ameliorated NTM-LD.
![Figure 6. Administration of capsular polysaccharide of P. copri ameliorated NTM-LD.](/cms/asset/6414e735-58bf-41f4-8cdf-5670844de18a/kgmi_a_2361490_f0006_oc.jpg)